香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 IMM2510（珀維拉芙普α）由本集團自主研發，是一款靶向血管內皮生長因子 (VEGF)及程序性細胞死亡配體1 (PD-L1)的雙特異性分子，採用單克隆抗體 — 受體重組蛋白(mAb-Trap)結構。IMM2510能夠抑制血管生成，使腫瘤縮小，並 使腫瘤細胞對免疫反應更敏感，同時通過阻斷PD-L1 ╱程序性細胞死亡蛋白1 (PD-1)相互作用及誘導Fc介導的抗體依賴的細胞毒性作用(ADCC) ╱抗體依賴的 細胞吞噬作用(ADCP)活性激活T細胞、自然殺傷細胞及巨噬細胞。 本公司與Axion Bio, Inc.（前稱為SynBioTx Inc.，Instil Bio, Inc. (NASDAQ：TI ...

Market Performance - The Hong Kong stock market saw all three major indices rise, with the Hang Seng Index up 0.72% to 25,967.98 points, the Tech Index up 0.48% to 5,951.45 points, and the National Enterprises Index up 0.83% to 9,300.74 points [2][4]. Oil Sector - Oil stocks experienced significant gains, with notable increases in shares of companies such as Yanchang Petroleum International (up 6.10%), CNOOC (up 2.15%), and PetroChina (up 1.52%) [4][5]. - The rise in oil stocks was attributed to U.S. sanctions on two major Russian oil companies, which led to a spike in WTI crude oil prices, currently around $60.59 [5]. Banking Sector - Bank stocks continued to attract investment, with Postal Savings Bank rising 4.59%, Agricultural Bank up 1.88%, and Industrial and Commercial Bank up 1.68% [6]. - According to Guotai Junan Securities, the banking sector is expected to maintain positive revenue growth, with projected increases in cumulative revenue and net profit for listed banks by 0.4% and 1.1% year-on-year, respectively, for the first three quarters of 2025 [6]. Insurance Sector - Insurance stocks also benefited from the trend towards dividend-paying stocks, with China People's Insurance Group rising 2.07%, China Pacific Insurance up 0.94%, and Prudential up 0.38% [6]. Lithium Battery Sector - Lithium battery stocks faced downward pressure, with BYD Electronics down 2.44%, CATL down 2.01%, and Zhongxin Innovation down 1.99% [8]. - Despite the overall decline, UBS raised the target price for CATL from HKD 495 to HKD 640, maintaining a "Buy" rating and increasing profit forecasts for 2025 and 2026 by 7% and 11%, respectively [9]. Pharmaceutical Sector - Pharmaceutical stocks continued to adjust, with Rongchang Bio down 10.93%, Yiming Oncology down 9.40%, and JAKS down 9% [10]. - Despite the short-term weakness, the industry fundamentals remain solid, with Shanghai's biopharmaceutical manufacturing sector growing by 3.6% in the first three quarters of this year [11]. Meituan's Strategic Moves - Meituan saw its stock rise 4.06%, with a peak increase of over 6% during the day, following the announcement of key personnel changes aimed at enhancing its overseas business strategy [12]. - Starting October 30, Meituan's brand Keeta will officially launch operations in Brazil, with initial pilot cities in Santos and São Vicente [12]. Pop Mart's Decline - Pop Mart's stock fell by 9.36% to HKD 232.40, as analysts expressed concerns over the sustainability of its revenue growth, predicting a peak in 2025 followed by a slowdown in 2026 [13].

Core Viewpoint - The company Yiming Anke-B (01541.HK) announced the issuance of 24.2 million shares according to a placement agreement, scheduled for October 16, 2025 [1] Group 1 - The issuance of shares is part of a placement agreement [1] - The total number of shares to be issued is 24.2 million [1] - The scheduled date for the issuance is October 16, 2025 [1]

Core Viewpoint - 宜明昂科-B (01541) announced the issuance of 24.2 million new H-shares based on a general authorization and a placement agreement dated October 9, 2025 [1] Group 1 - The company will allocate and issue a total of 24.2 million new H-shares [1]

Group 1 - The company, Yiming Anke-B (01541), announced the issuance of 24.2 million new H-shares based on a general authorization and a placement agreement dated October 9, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01541 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | ...

Market Overview - Concerns over tariffs have led to a decline in Hong Kong stocks, with the Hang Seng Index closing down 0.09% at 25,888.51 points and a total trading volume of 275.43 billion HKD [1] - The Hang Seng Technology Index fell by 1.18%, indicating weakness in the tech sector, while the Hang Seng China Enterprises Index saw a slight increase of 0.09% [1] Blue-Chip Stocks Performance - Pop Mart (09992) continued its upward trend, closing up 5.57% at 288.2 HKD, contributing 17.6 points to the Hang Seng Index [2] - Morgan Stanley upgraded Pop Mart's investment rating to "Overweight," raising the target price from 300 HKD to 320 HKD, citing attractive valuation and upcoming catalysts [2] - Other notable blue-chip performances included New Oriental (09901) up 8.86% and BYD Electronics (00285) up 5.01%, while Xiaomi Group (01810) and SMIC (00981) faced declines of 3.6% and 2.76%, respectively [2] Sector Performance - Large tech stocks showed weak performance, with Xiaomi down 3.6%, Tencent down 1.12%, and Alibaba down 0.25% [3] - Coal and banking stocks performed well, with China Coal Energy rising over 7% and Agricultural Bank of China up nearly 3% [3] - The pharmaceutical sector continued to rise, with notable gains from Xuan Bamboo Biotechnology (02575) up 10.27% and Honor Bio (09995) up 4.77% [3] New Consumption Trends - The new consumption sector showed mixed results, with Lao Pu Gold (06181) up 6.21% and Pop Mart (09992) up 5.57%, while Giant Bio (02367) fell over 15% [4] - Morgan Stanley highlighted Lao Pu Gold as a top pick in the Chinese consumer sector, noting a clear trend in brand value enhancement [4] Dividend Stocks Activity - Dividend stocks were active, with China Coal Energy (01898) up 7.26% and Agricultural Bank of China (01288) up 2.98% [5] - The market is shifting focus towards geopolitical risks, corporate earnings fundamentals, and policy effects, with a potential rotation towards value and dividend stocks [5] Apple-Related Stocks - Several Apple-related stocks saw gains, including BYD Electronics (00285) up 5.01% and Hong Teng Precision (06088) up 3.05% [6] - Recent visits by Apple executives to key suppliers in China indicate ongoing collaboration and investment in the region [6] Notable Stock Movements - Yunji (02670) debuted with a significant gain of 26.05%, closing at 120.5 HKD, as a leading AI-enabled robotics service provider [7] - Think Academy (01769) surged 26.48% after announcing a share issuance to enhance educational quality and fund AI projects [8] - Fenbi (02469) rose 7.09% following strong market response to its AI-driven exam preparation system [9] - Sanhua Intelligent Control (02050) fell 6.13% after clarifying rumors about large robot orders were untrue [10] - Hong Kong Telecom (06823) faced a decline of 4.37% due to potential operational license revocation in the U.S. [11]

Core Viewpoint - Yiming Anke-B (01541.HK) has successfully completed a placement agreement, raising approximately HKD 345.1 million for various research and operational purposes [1] Group 1: Placement Details - The placement involved the successful allocation of 24.2 million shares at a price of HKD 14.50 per share, representing about 5.94% of the company's issued share capital prior to the placement [1] - The shares allocated account for approximately 6.11% of the total issued H-shares before the placement and about 5.61% and 5.76% of the issued share capital and H-shares, respectively, after the placement [1] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors [1] - About 20% will be used for the development of IMM01 (Tideglusib) [1] - Approximately 10% will be directed towards the research of IMM0306 [1] - The remaining 30% will be utilized to supplement the company's working capital and for general corporate purposes [1]

Core Viewpoint - The company has successfully completed the placement agreement, with all conditions met and the delivery executed on October 16, 2025 [1] Summary by Relevant Sections - The placement agent has successfully allocated a total of 24.2 million shares at a price of HKD 14.50 per share to no fewer than six subscribers [1] - This allocation represents approximately 5.94% of the company's issued share capital prior to the delivery and about 6.11% of the total issued H shares [1] - Following the delivery and issuance of the placement shares, the allocated shares will account for approximately 5.61% of the company's enlarged issued share capital and about 5.76% of the total issued H shares [1]

Core Viewpoint - The company, Yiming Anke-B (01541), has successfully completed the placement agreement, with all conditions met and the delivery executed according to the terms on October 16, 2025 [1] Group 1: Placement Agreement Details - The placement agent has successfully placed a total of 24.2 million shares at a price of HKD 14.50 per share to no less than six subscribers [1] - This placement represents approximately 5.94% of the company's issued share capital immediately before the delivery and about 6.11% of the total issued H shares [1] - After the placement, the shares will account for approximately 5.61% of the company's issued share capital and about 5.76% of the total issued H shares [1]